Filing Analysis
Material Agreement
Filed Apr 22, 2026
MEDIUM
Rafael Holdings announced that its subsidiary, Cyclo Therapeutics, LLC, has entered into an exclusive licensing agreement with the Massachusetts Institute of Technology (MIT). The agreement covers a patent for the use of cyclodextrins to treat Alzheimer's Disease patients carrying the ApoE4 genetic mutation.
Key Facts
- Exclusive licensing agreement with MIT for U.S. Patent No. 12285440.
- The patent focuses on Alzheimer's Disease (AD) patients with the ApoE4 genetic mutation.
- The agreement was announced on April 22, 2026.
- The technology involves the use of cyclodextrins.
Regulation FD Disclosure
Filed Mar 16, 2026
LOW
Rafael Holdings, Inc. announced its financial results for the fiscal quarter ended January 31, 2026. The company furnished the earnings release via Item 2.02 and included the full press release as an exhibit.
Key Facts
- The filing reports results for the fiscal quarter ended January 31, 2026.
- The report was filed on March 16, 2026.
- The earnings release was furnished as Exhibit 99.1.
- The information is furnished under Item 2.02 (Results of Operations and Financial Condition) and is not deemed 'filed' for liability purposes.
Disclaimer: This analysis is generated by AI and is for informational purposes only.
It does not constitute financial advice, investment recommendations, or an offer to buy or sell securities.
Always review the original SEC filings and consult a financial advisor before making investment decisions.